ALPN — Alpine Immune Sciences Income Statement
0.000.00%
Last trade - 00:00
- $4.46bn
- $4.15bn
- $58.88m
- 56
- 12
- 79
- 47
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.74 | 9.34 | 23.4 | 30.1 | 58.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 45.3 | 38.1 | 73.3 | 88.2 | 103 |
Operating Profit | -43.6 | -28.7 | -49.9 | -58.1 | -44.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -41.9 | -27.9 | -50.4 | -55.4 | -32.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -41.9 | -27.9 | -50.3 | -57.8 | -32.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -41.9 | -27.9 | -50.3 | -57.8 | -32.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -41.9 | -27.9 | -50.3 | -57.8 | -32.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.28 | -1.34 | -1.98 | -1.73 | -0.644 |